Shares of Juno Therapeutics Inc (NASDAQ:JUNO) closed yesterday up 15% following the announcement of the company’s collaboration with Celgene Corporation. In response, J.
On June 29, Juno Therapeutics Inc (NASDAQ:JUNO) and Celgene Corporation (NASDAQ:CELG) announced a ten-year collaboration to develop new therapies for cancer and auto-immune …
The modern pharmaceutical industry as we know it is one of the newest industries in the world. This is because the tools that …
Wall Street analysts are weighing today on Celgene Corporation (NASDAQ:CELG) after the pharmaceutical giant announced a 10-year broad collaboration with Juno Therapeutics Inc (NASDAQ:JUNO) to advance T-cell …
Global X Funds (NYSEARCA:GREK) shares are up 3.4% in pre-market trading to $9.
Celgene Corporation (NASDAQ:CELG) has placed its bet in the race to develop and market T cell therapies for oncology with a $1 billion …
Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced the U.S.
Recently, various executives have taken part in insider selling activity for the stocks of Walt Disney Co (NYSE:DIS), Oracle Corporation (NYSE:ORCL), Juno Therapeutics Inc (NASDAQ:JUNO), and Veeva Systems …
Oracle Corporation (NYSE:ORCL) fell -6.3% in pre-market trading to $42.
In a research report released today, Maxim Group analyst Jason McCarthy initiated coverage on shares of Juno Therapeutics Inc (NASDAQ:JUNO) with a Buy rating and a …
